What is it about?
There has been a growing number of oncology drug approvals. Non-interventional post-authorization safety/effectives studies (PASSs/PAESs) aim to provide real-world evidence (RWE) on the safety/effectiveness of oncology drugs post-approval. This article provided a summary of the characteristics such study design and data sources of current non-interventional PASSs/PAESs that aimed to generate RWE for oncology drugs.
Photo by Tim Chow on Unsplash
Why is it important?
Findings of this study help us better understand the current landscape of oncology-specific non-interventional PASSs/PAESs and provide insights for the future design of non-interventional PASSs/PAESs studies for oncology drugs.
Read the Original
This page is a summary of: Regulator‐Requested Non‐Interventional Postauthorization Safety and Effectiveness Studies for Oncology Drugs: A Systematic Review, Clinical Pharmacology & Therapeutics, November 2021, Wiley, DOI: 10.1002/cpt.2450.
You can read the full text:
The following have contributed to this page